Have you ever wondered why so many clinical trials fail before reaching the market? In this episode, we dive deep into the hidden challenges of clinical trials with Rob Freishtat, President and Co-Founder of Uncommon Cures and a professor at George Washington University School of Medicine and Health Sciences.

Rob shares insider knowledge on why over 55% of clinical trials fail, the high costs of drug development, and how misaligned priorities between researchers, regulators, and sponsors can derail promising treatments. He also reveals how streamlining clinical trials, improving patient recruitment, and leveraging AI and real-world data can help bring life-saving drugs to market faster.

If you're curious about the future of medicine, drug approvals, or how rare disease treatments are developed, this is an episode you don’t want to miss!

Chapters:

00:00 Introduction – Why Clinical Trials Matter
02:59 The Real Reason Many Clinical Trials Fail
08:18 Where the Industry Wastes the Most Money
15:28 How Misalignment in Drug Development Happens
27:00 The Future of AI in Clinical Trials
34:19 How to Fix Broken Clinical Trials
41:03 Final Thoughts & Key Takeaways

🔗 Links Mentioned:
🌐 Visit Uncommon Cures
📌 Follow Rob Freishtat on LinkedIn

More from Life Sciences 360:
🎥 Youtube:/ @lifesciences360

For transcripts, check out the podcast website - www.lifesciencespod.com